Genaissance Pharmaceuticals and AstraZeneca sign pharmacogenomics based agreement

Agreement continues the commercialization of the STRENGTH study

15.09.2003

Genaissance Pharmaceuticals, Inc. announced that it has entered into a licensing agreement with AstraZeneca PLC to utilize information generated from Genaissance's Statin Response Examined by Genetic Haplotype Markers (STRENGTH) study. Under the terms of the agreement, AstraZeneca will receive non-exclusive access to the STRENGTH study database for research purposes for a limited period. This marks the second commercialization agreement related to the proprietary data generated in Genaissance's STRENGTH study.

"We are pleased to enter into this new agreement with AstraZeneca," said Kevin Rakin, President and CEO of Genaissance. "Such agreements demonstrate our continued effort to commercialize and build on our internal programs such as STRENGTH."

The licensing arrangement is focused on proprietary data generated in the STRENGTH study. This study of more than 400 patients demonstrated that gene variations are associated with response to treatment with the statin class of drugs. Conducted over 16 weeks, the STRENGTH study prospectively analyzed for an association between an individual's genetics and the clinical effectiveness of three statins (atorvastatin, pravastatin and simvastatin) in reducing LDL- cholesterol. Initial results of this study were presented at the 52nd Annual American College of Cardiology Scientific Session in March 2003.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines and DNA-based diagnostics. Genaissance markets its technology, clinical development skills and pharmacogenetic services to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with major pharmaceutical, diagnostic and biotechnology companies. Genaissance is headquartered in Science Park in New Haven, Connecticut.

https://www.bionity.com/de/news/28611/genaissance-pharmaceuticals-and-astrazeneca-sign-pharmacogenomics-based-agreement.html